Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
E-pub ahead of print

Benefits and harm of paracetamol and ibuprofen in combination for postoperative pain: preplanned subgroup analyses of the multicenter randomized PANSAID trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Time to onset of gastrointestinal bleeding in the SUP-ICU trial: a preplanned substudy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Use of red blood cells in Danish intensive care units: A population-based register study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Heterogeneity of treatment effect of stress ulcer prophylaxis in ICU patients: A secondary analysis protocol

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Pantoprazole in ICU patients at risk for gastrointestinal bleeding-1-year mortality in the SUP-ICU trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Storage time of red blood cells among ICU patients with septic shock

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: The 'Paracetamol and Ibuprofen in Combination' (PANSAID) trial showed that combining paracetamol and ibuprofen resulted in lower opioid consumption than each drug alone and we did not findan increase in risk of harm when using ibuprofen versus paracetamol. The aim of this subgroup analysis was to investigate differences in benefits and harms of the interventions in different subgroups. We hypothesized the intervention effects would differ in subgroups with different risk of pain or adverse events.

METHODS: In these preplanned subgroup analyses of the PANSAID trial population, we assessed subgroup heterogeneity in intervention effects between 1) subgroups (sex, age, use of analgesics, American Society of Anesthesiologists score, and type of anesthesia) and morphine consumption, and 2) subgroups (sex, age, use of non-steroidal anti-inflammatory drugs, and American Society of Anesthesiologists score) and serious adverse events.

RESULTS: Test of interaction between age and the pairwise comparison between paracetamol 1 g versus paracetamol 0.5 g + ibuprofen 200 mg (P=0.009) suggested lower morphine consumption in patients>65 years. However, post hoc analyses of related outcomes showed no interaction for this pairwise comparison. All other tests of interaction regarding both benefit and harm were not statistically significant.

CONCLUSION: These preplanned subgroup analyses did not suggest that patients in the investigated subgroups benefitteddifferently from a basic non-opioid analgesic regimen consisting of paracetamol and ibuprofen. Further, there was no evidence of subgroup heterogeneity regarding harm and use of ibuprofen. Because of reduced statistical power in subgroup analyses we cannot exclude clinically relevant subgroup heterogeneity.

OriginalsprogEngelsk
TidsskriftActa Anaesthesiologica Scandinavica
ISSN0001-5172
DOI
StatusE-pub ahead of print - 24 okt. 2019

Bibliografisk note

© 2019 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

ID: 58261551